Ana Chudzinski-Tavassi

Dr. Ana Chudzinski-Tavassi

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2018 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
LPLorena Favaro Pavon
Lorena Favaro Pavon
TSTatiana Tais Sibov
Tatiana Tais Sibov
ASAndrea Vieira de Souza
Andrea Vieira de Souza
ECEdgar Ferreira da Cruz
Edgar Ferreira da Cruz
SMSuzana M. F. Malheiros
Suzana M. F. Malheiros
SCSérgio Cavalheiro
Sérgio Cavalheiro
Previous studies have demonstrated remarkable tropism of mesenchymal stem cells (MSCs) toward malignant gliomas, making these cells a potential vehicle for delivery of therapeutic agents to disseminated glioblastoma (GBM) cells. However, the potential contribution of MSCs to tumor progression is a matter of concern. It has been suggested that CD133+ GBM stem cells secrete a variety of chemokines, including monocytes chemoattractant protein-1 (MCP-1/CCL2) and stromal cell-derived factor-1(SDF-1/CXCL12), which could act in this tropism. However, the role in the modulation of this tropism of the subpopulation of CD133+ cells, which initiate GBM and the mechanisms underlying the tropism of MSCs to CD133+ GBM cells and their effects on tumor development, remains poorly defined. We found that isolated and cultured MSCs (human umbilical cord blood MSCs) express CCR2 and CXCR4, the respective receptors for MCP-1/CCL2 and SDF-1/CXCL12, and demonstrated, in vitro, that MCP-1/CCL2 and SDF-1/CXC12, secreted by CD133+ GBM cells from primary cell cultures, induce the migration of MSCs. In addition, we confirmed that after in vivo GBM tumor establishment, by stereotaxic implantation of the CD133+ GBM cells labeled with Qdots (705 nm), MSCs labeled with multimodal iron oxide nanoparticles (MION) conjugated to rhodamine-B (Rh-B) (MION-Rh), infused by caudal vein, were able to cross the blood-brain barrier of the animal and migrate to the tumor region. Evaluation GBM tumors histology showed that groups that received MSC demonstrated tumor development, glial invasiveness, and detection of a high number of cycling cells. Therefore, in this study, we validated the chemotactic effect of MCP-1/CCL2 and SDF-1/CXCL12 in mediating the migration of MSCs toward CD133+ GBM cells. However, we observed that, after infiltrating the tumor, MSCs promote tumor growth in vivo probably by release of exosomes. Thus, the use of these cells as a therapeutic carrier strategy to target GBM cells must be approached with caution.

4 September 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CTCatarina F P Teixeira
Catarina F P Teixeira
CFCristina Maria Fernandes
Cristina Maria Fernandes
ELElbio Leiguez
Elbio Leiguez
ACAna Chudzinski-Tavassi
Ana Chudzinski-Tavassi
Envenomation by viperid snakes is characterized by systemic thrombotic syndrome and prominent local inflammation. To date, the mechanisms underlying inflammation and blood coagulation induced by Viperidae venoms have been viewed as distinct processes. However, studies on the mechanisms involved in these processes have revealed several factors and signaling molecules that simultaneously act in both the innate immune and hemostatic systems, suggesting an overlap between both systems during viper envenomation. Moreover, distinct classes of venom toxins involved in these effects have also been identified. However, the interplay between inflammation and hemostatic alterations, referred as to thromboinflammation, has never been addressed in the investigation of viper envenomation. Considering that platelets are important targets of viper snake venoms and are critical for the process of thromboinflammation, in this review, we summarize the inflammatory effects and mechanisms induced by viper snake venoms, particularly from the Bothrops genus, which strongly activate platelet functions and highlight selected venom components (metalloproteases and C-type lectins) that both stimulate platelet functions and exhibit pro-inflammatory activities, thus providing insights into the possible role(s) of thromboinflammation in viper envenomation.

1 October 2016 in Pharmacological Research
Verified
Journal Article
Closed access
VZV.O. Zambelli
V.O. Zambelli
KPK.F.M. Pasqualoto
K.F.M. Pasqualoto
GPGisele Picolo
Gisele Picolo
ACAna Chudzinski-Tavassi
Ana Chudzinski-Tavassi
YCYara Cury
Yara Cury

3 June 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
SASonia Aparecida de Andrade
Sonia Aparecida de Andrade
DSDaniel Alexandre de Souza
Daniel Alexandre de Souza
ATAmarylis Lins Torres
Amarylis Lins Torres
CLCristiane Ferreira Graça de Lima
Cristiane Ferreira Graça de Lima
MEMatteo Celano Ebram
Matteo Celano Ebram
ACAna Chudzinski-Tavassi
Ana Chudzinski-Tavassi
The COVID-19 pandemic, caused by SARS-CoV-2, had its first cases identified in late 2019 and was considered a clinical pandemic in March 2020. In March 2022, more than 500 million people were infected and 6,2 million died as a result of this disease, increasingly associated with changes in human hemostasis, such as hypercoagulation. Numerous factors contribute to the hypercoagulable state, and endothelial dysfunction is the main one, since the activation of these cells can strongly activate platelets and the coagulation system. In addition, there is a dysregulation of the renin-angiotensin system due to the SARS-CoV-2 takeover of the angiotensin converting enzyme 2, resulting in a strong immune response that could further damage the endothelium. Thrombus formation in the pulmonary microvasculature structure in patients with COVID-19 is an important factor to determine the severity of the clinical picture and the outcome of this disease. This review describes the hemostatic changes that occur in SARS-CoV-2 infection, to further improve our understanding of pathogenic mechanisms and the interaction between endothelium dysfunction, kallikrein-kinins, renin angiotensin, and the Coagulation/fibrinolysis systems as underlying COVID-19 effectors. This knowledge is crucial for the development of new effective therapeutic approaches, attenuating the severity of SARS-CoV-2’s infection and to reduce the deaths.

Verified
Journal Article
Open access
PDF file
CDCarlos DeOcesano-Pereira
Carlos DeOcesano-Pereira
Raquel MachadoRaquel Machado
Raquel Machado
ACAna Chudzinski-Tavassi
Ana Chudzinski-Tavassi
MSMari Sogayar
Mari Sogayar
Non-coding RNAs (ncRNAs) comprise a diversity of RNA species, which do not have the potential to encode proteins. Non-coding RNAs include two classes of RNAs, namely: short regulatory ncRNAs and long non-coding RNAs (lncRNAs). The short regulatory RNAs, containing up to 200 nucleotides, include small RNAs, such as microRNAs (miRNA), short interfering RNAs (siRNAs), piwi-interacting RNAs (piRNAs), and small nucleolar RNAs (snoRNAs). The lncRNAs include long antisense RNAs and long intergenic RNAs (lincRNAs). Non-coding RNAs have been implicated as master regulators of several biological processes, their expression being strictly regulated under physiological conditions. In recent years, particularly in the last decade, substantial effort has been made to investigate the function of ncRNAs in several human diseases, including cancer. Glioblastoma is the most common and aggressive type of brain cancer in adults, with deregulated expression of small and long ncRNAs having been implicated in onset, progression, invasiveness, and recurrence of this tumor. The aim of this review is to guide the reader through important aspects of miRNA and lncRNA biology, focusing on the molecular mechanism associated with the progression of this highly malignant cancer type.

1 October 2016 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
VBVania G. Branco
Vania G. Branco
AIAsif Iqbal
Asif Iqbal
MAMiryam Paola Alvarez-Flores
Miryam Paola Alvarez-Flores
JSJuliana Mozer Sciani
Juliana Mozer Sciani
SASonia A. de Andrade
Sonia A. de Andrade
ACAna Chudzinski-Tavassi
Ana Chudzinski-Tavassi